Close Menu

lawsuit

In the lawsuit, which comes just days after Alnylam said it settled a different suit related to the IP, the University of Utah alleges that one of its researchers actually invented the technology covered by the Tuschl-II patent estate.

The new offer comes a month after Signal filed suit against Med BioGene for negotiating a licensing deal for the LungExpress Dx test with Precision Therapeutics.

Tekmira alleges that Alnylam has, among other things, illegally used its proprietary technology to develop new versions of lipid nanoparticle delivery agents.

Alnylam said that as part of the agreement, it would allow Merck, the parent company of one-time rival Sirna Therapeutics, to sub-license a portion of the disputed IP to which it previously did not have access.

In making its decision, the court said that Mirinia has “raised only serious questions” on the merits of its trademark infringement claim, and not shown that it would suffer “irreparable harm” if Marina is allowed to continue using its newly acquired moniker.

The suit was filed in early November and accused PacBio of luring away at least 15 of Affymetrix's former employees.

Signal filed its suit against Med BioGene earlier this month alleging a breach of agreement, violation of a confidentiality agreement, and misuse of proprietary information, among other charges.

Signal has alleged that Med BioGene breached the provisions in a term sheet inked between the two companies regarding an exclusive, worldwide license for Med BioGene's LungExpress Dx test.

The action is an amendment to a lawsuit in which plaintiffs argued that the company, its board, and certain of its officers breached their fiduciary duty in connection to the company's trouble with its Accutn1 troponin test last year.

As a result, it will be up to the new court to rule on CSHL's allegations that the law firm Ropes & Gray mishandled certain RNAi-related intellectual property stemming from the work of Greg Hannon and maintained improper business relationships with RNAi drug developers.

Pages

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.